Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Adv Healthc Mater. 2017 Dec 6;7(6):e1701024. doi: 10.1002/adhm.201701024

Table 1.

Representative anticancer drug, gene, and virus encapsulation into electrospun nanofibers with varied polymer compositions.

Drug Carrier Loading
method
Type of cancer Refs
CPT11, SN-38 PCL/PGC-C18 Encapsulation Colorectal cancer [27]
Cisplatin PEO/PLA; PCL/PGC-C18 Encapsulation Cervical cancer; lung cancer [28]
Doxorubicin Chitosan/PLA; PLGA/HAp; PLA/mesoporous silica nanoparticles; poly(NIPAAm-co-HMAAm); silica nanoparticles-DOX-CaCO3/PLLA; polydopamine/PCL; gelatin/PCL-PEG micelle; Encapsulation Immobilization Graffi myeloid tumor; epithelial carcinoma; orthotopic secondary hepatic carcinoma; postsurgical cancer; skin cancer; HeLa cells; H1299 cells; breast cancer [29]
Doxorubicin and camptothecin PLGA/gelatin/ZnO nanospheres Encapsulation Liver cancer [30]
Paclitaxel PLGA; Chitosan/PEO Encapsulation Glioma; prostate cancer [31]
Paclitaxel and doxorubicin PEG-PLA Encapsulation Glioma [32]
5-aminolevulinic acid PVA Encapsulation Cholangiocarcinoma [33]
Hydroxycamptothecin PEG-PDLA Encapsulation Hepatoma [34]
Combretastatin A-4 and hydroxycamptothecin PEG-PLA Encapsulation Breast cancer [35]
Titanocene dichloride PLLA Encapsulation Lung cancer [36]
Temozolomide PLGA/PLA/PCL Encapsulation Glioma [15]
1,3-bis(2-chloroethyl)-1-nitrosourea PEG-PLLA Encapsulation Glioma [37]
Green tea polyphenols PCL/MWCNTs Encapsulation Lung cancer and liver cancer [38]
Curcumin PCL-PEG-PCL; PLGA Encapsulation Glioma; skin [39]
Daunorubicin Poly(N-isopropylacrylamide)-co-polystyrene; Encapsulation Leukemia [40]
Daunorubicin and Fe3O4nanoparticles PLA Encapsulation Leukemia [41]
Cdk2 siRNA plasmid DNA/PCL Encapsulation Breast cancer [42]
MMP-2 RNAi and Paclitaxel PEI/DNA nanoparticles/PLGA Encapsulation brain tumor [43]
Inactivated sendai virus PCL Surface immobilization Prostate cancer [44]
Fe3O4 nanoparticles Chitosan Surface immobilization Colon adenocarcinoma [45]
HHS Vulnerability Disclosure